13877-56-0

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrazolo[4,3-d]pyrimidin-7-amine (9CI) is used as a lead compound for the development of new drugs, leveraging its antimicrobial, anti-inflammatory, and antitumor properties. Its potential as an enzyme inhibitor also makes it a valuable candidate for the creation of targeted therapies.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1H-Pyrazolo[4,3-d]pyrimidin-7-amine (9CI) serves as a subject of study for understanding its structure-activity relationships and optimizing its pharmacological properties. This research aids in the design of more effective and safer drugs based on its molecular framework.
Used in Drug Discovery:
1H-Pyrazolo[4,3-d]pyrimidin-7-amine (9CI) is utilized in drug discovery processes to identify novel therapeutic agents with improved efficacy and selectivity. Its unique chemical structure and biological activities make it a promising starting point for the development of innovative treatments for various diseases and conditions.

InChI:InChI=1/C5H5N5/c6-5-4-3(1-9-10-4)7-2-8-5/h1-2H,(H,9,10)(H2,6,7,8)

Upstream product

• 60355-61-5 7-(methylthio)-1H-pyrazolo[4,3-d]pyrimidine 
• 13877-55-9 pyrazolo<4,3-d>pyrimidin-7-one 
• 120614-05-3 1,6-dihydro-pyrazolo[4,3-d]pyrimidine-7-thione 
• 68703-67-3 4-amino-1H-pyrazole-5-carbonitrile 
• 3473-63-0 formamidine acetic acid 
• 61241-07-4 4-nitro-1H-pyrazole-3-carbonitrile 

Downstream Products

• 162791-82-4 7-amino-3-iodopyrazolo<4,3-d>pyrimidine 

Relevant academic research and scientific papers

Palladium-mediated coupling reactions of an amino-substituted heterocycle. Direct synthesis of C-nucleosides related to adenosine

C-Nucleosides of the pyrazolo [1,5-a]-1,3,5-triazine aglycon system have been prepared by palladium-mediated coupling of 8-iodopyrazolo[1,5-a]-1,3,5-triazines. 4-(N,N'-Diisobutyloxycarbonyl)amino-8-iodopyrazolo[1,5-a]-1,3, 5-triazi ne and the furanoid gly

Kinase inhibitors

The present application is directed to pyrazolopyrirnidine and furopyrimidine analogs of the formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.